综合电商模板

Stemcell  73482  Tivantinib

Product Overview

Tivantinib is a staurosporine derivative which binds to inactive, dephosphorylated MET receptor tyrosine kinase, in a manner that is not competitive with ATP (Munshi et al.; Eathiraj et al.). It is selective for MET (Ki ≅ 355 nM) in a screen of 230 kinases (Munshi et al.). It also shows cytotoxic activity which is distinct from its inhibition of MET (Basilico et al.; Katayama et al.). It has also been shown to bind directly to the colchicine binding pocket of tubulin, thereby reducing tubulin polymerization (Aoyama et al.).

CANCER RESEARCH

· Induces apoptosis of human myeloma CD138+ plasma cells in vitro, and demonstrates efficacy in a mouse xenograft model of myeloma (Zaman et al.).

· Inhibits metastatic growth of breast cancer cells in bone and reduces tumor-induced osteolysis, in a mouse xenograft model (Previdi et al.).

· Perturbs microtubule dynamics, induces G2/M arrest, and promotes apoptosis independently of c-MET inhibition in a variety of cancer cell lines (Basilico et al.).

CAS Number:905854-02-6

Alternative Names:ARQ 197

Chemical Formula:C₂₃H₁₉N₃O₂

Molecular Weight:369.4 g/mol

Purity:≥ 98%

Pathway:HGF

Target:MET

Related products

Uante,您的科研物资战略合作伙伴！

重庆市寰宇安泰生物科技有限公司